News
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
EQS-News: Abivax reports 2022 financial results and operations update
EQS-News: Abivax reports 2022 financial results and operations update
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
EQS-News: Abivax appoints Michael Ferguson as Chief Commerical Officer
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
EQS-News: Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis
Convatec Group PLC: Scrip Dividend - Calculation Price
Convatec Group PLC: Scrip Dividend - Calculation Price
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
EQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
EQS-News: Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair
Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
Relief Therapeutics Announces Executive Leadership Team Change
Relief Therapeutics Announces Executive Leadership Team Change
EQS-News: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
EQS-News: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings
Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc
Form 8.3 - The Vanguard Group, Inc.: Jounce Therapeutics Inc